Enhanced PTSD Communication Strategies for Post-Traumatic Stress Disorder
(AWARE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if adding a writing exercise called AWARE can enhance existing PTSD treatments. Researchers will test two common PTSD therapies—cognitive processing therapy (CPT) and prolonged exposure (PE)—with and without AWARE to assess whether it improves patient communication with therapists and treatment outcomes. The trial targets adults with PTSD who have maintained stable psychiatric medication for at least four weeks. Participants will receive either CPT or PE, with or without the AWARE writing task. The goal is to discover if this new approach enhances treatment outcomes. As an unphased trial, this study provides a unique opportunity to explore innovative methods for improving PTSD treatment outcomes.
Will I have to stop taking my current medications?
The trial requires that participants have been stable on their psychiatric medications for at least 4 weeks, so you will not need to stop taking your current medications if they are stable.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that expressive writing, like that used in the AWARE program, is generally safe and well-received by people with PTSD. One study found that while expressive writing did not change PTSD diagnoses or symptoms, patients managed it well. This suggests that adding AWARE, which includes writing tasks to enhance communication between patients and therapists, is unlikely to cause harm.
Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE) are both proven and effective treatments for PTSD. Experts widely recommend these treatments as the best available, and they have been safely used by many patients over the years.
Overall, existing evidence supports the safety of all parts of the trial's treatments. Participants can feel confident that these therapies are well-researched and generally well-tolerated.12345Why are researchers excited about this trial?
Researchers are excited about these treatments for PTSD because they integrate traditional therapies with a fresh approach that could enhance their effectiveness. Unlike the standard cognitive processing therapy (CPT) and prolonged exposure (PE), which rely solely on therapeutic sessions, the AWARE intervention adds a unique writing component designed to boost patient response and engagement. This adjunctive writing element aims to deepen the therapeutic impact by encouraging patients to articulate and process their experiences more thoroughly. By potentially amplifying the effects of CPT and PE, AWARE could lead to more significant improvements in PTSD symptoms, offering a promising advancement in how we approach treatment for this condition.
What evidence suggests that this trial's treatments could be effective for PTSD?
Studies have shown that cognitive processing therapy (CPT) and prolonged exposure (PE) effectively treat PTSD and rank highly in clinical practice guidelines. In this trial, participants will be randomized into different arms to receive either CPT or PE. One arm will include the adjunctive writing intervention, AWARE, which aims to amplify response and engagement. Research suggests that additional methods like AWARE might enhance these therapies. Although AWARE is still being tested, similar writing activities have been safe and well-received by PTSD patients, aiming to increase patient involvement and improve results during therapy.13678
Who Is on the Research Team?
Elizabeth Alpert, PhD
Principal Investigator
National Center for PTSD at VA Boston Healthcare System, BU School of Medicine, Psychiatry
Are You a Good Fit for This Trial?
This trial is for adults with PTSD who are stable on psychiatric medications for at least a month. It's not suitable for individuals with unstable bipolar disorder, psychosis, severe substance use needing immediate attention, active suicidal or homicidal thoughts, those already in trauma-focused treatment, or with cognitive impairments like advanced dementia.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Case Series Phase
CPT or PE with AWARE provided to four adults with PTSD to pilot test and refine AWARE
Randomized Controlled Trial (RCT) Phase
50 adults with PTSD randomized to receive either CPT/PE as usual or CPT/PE with AWARE
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Adjunctive writing to amplify response and engagement (AWARE)
- Cognitive processing therapy (CPT)
- Prolonged exposure (PE)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Boston University
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator